These Analysts Revise Their Forecasts On Harrow Following Q4 Results

Benzinga

03/04

Harrow Inc. (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.

The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.

During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.

Harrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.

Harrow shares rose 3% to $39.76 in pre-market trading.

These analysts made changes to their price targets on Harrow following earnings announcement.

HC Wainwright & Co. analyst Yi Chen maintained Harrow with a Buy and raised the price target from $69 to $70.
Cantor Fitzgerald analyst Steve Seedhouse maintained the stock with an Overweight rating and lowered the price target from $94 to $91.

Considering buying HROW stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2616155685"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616155685\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616155685?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616155685","market":"us","top_or_hot":-1,"title":"These Analysts Revise Their Forecasts On Harrow Following Q4 Results","media":"Benzinga","content":"<html><body><p><strong>Harrow Inc.</strong> (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.</p>\n<p>The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.</p>\n<p>During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.</p>\n<p>Harrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.</p>\n<p>Harrow shares rose 3% to $39.76 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Harrow following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Yi Chen maintained Harrow with a Buy and raised the price target from $69 to $70.</li>\n<li>Cantor Fitzgerald analyst Steve Seedhouse maintained the stock with an Overweight rating and lowered the price target from $94 to $91.</li>\n</ul>\n<p><strong>Considering buying HROW stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"520\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-1024x520.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-1024x520.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-768x390.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74.png 1222w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Revise Their Forecasts On Harrow Following Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Revise Their Forecasts On Harrow Following Q4 Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2026-03-04 22:07</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>Harrow Inc.</strong> (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.</p>\n<p>The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.</p>\n<p>During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.</p>\n<p>Harrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.</p>\n<p>Harrow shares rose 3% to $39.76 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Harrow following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Yi Chen maintained Harrow with a Buy and raised the price target from $69 to $70.</li>\n<li>Cantor Fitzgerald analyst Steve Seedhouse maintained the stock with an Overweight rating and lowered the price target from $94 to $91.</li>\n</ul>\n<p><strong>Considering buying HROW stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"520\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-1024x520.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-1024x520.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74-768x390.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/04090607/image-74.png 1222w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51033887/these-analysts-revise-their-forecasts-on-harrow-following-q4-results","article_id":"2616155685","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616155685","pubTimestamp":1772633255,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4557":"大麻股","HROW":"Harrow Health Inc"},"translate_title":"这些分析师在第四季度业绩公布后修改了对哈罗的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Inc. (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.\nThe eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.\nDuring the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.\nHarrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.\nHarrow shares rose 3% to $39.76 in pre-market trading.\nThese analysts made changes to their price targets on Harrow following earnings announcement.\n\nHC Wainwright & Co. analyst Yi Chen maintained Harrow with a Buy and raised the price target from $69 to $70.\nCantor Fitzgerald analyst Steve Seedhouse maintained the stock with an Overweight rating and lowered the price target from $94 to $91.\n\nConsidering buying HROW stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}